Palvella Therapeutics (PVLA) Change in Cash (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Change in Cash for 14 consecutive years, with $148.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash rose 1960.73% year-over-year to $148.4 million; the TTM figure through Mar 2026 stood at $130.8 million (up 88.49% YoY), while the FY2025 annual figure was -$25.6 million, down 133.6% from the prior year.
• Change in Cash improved to $148.4 million in Q1 2026 per PVLA's latest filing, from -$5.6 million in the prior quarter.
• Across five years, Change in Cash topped out at $148.4 million in Q1 2026 and bottomed at -$34.0 million in Q1 2022.
• Historically, Change in Cash has averaged $6.5 million across 5 years, with a median of -$5.2 million in 2025.
• Annual changes were most pronounced in 2024 — Change in Cash surged 2442.84% — and 2025, when it plunged 1980.61%.
• Palvella Therapeutics' Change in Cash stood at -$9.8 million in 2022, then jumped by 69.74% to -$3.0 million in 2023, then soared by 2442.84% to $69.4 million in 2024, then sank by 108.05% to -$5.6 million in 2025, then jumped by 2757.33% to $148.4 million in 2026.
• Business Quant data shows PVLA's Change in Cash at $148.4 million in Q1 2026, -$5.6 million in Q4 2025, and -$6.9 million in Q3 2025.